Reviews/Motor Neurone Disease Treatment/Edaravone slows decline
DMT · MND-DMT-02 · v2
The strongest evidence here is a single randomised, placebo-controlled trial [1] that enrolled a carefully selected group of early-stage patients and found that edaravone slowed decline on a standard ALS function scale. That same trial states plainly that it gives no reason to expect benefit in patients outside that narrow group. Two further analyses that look supportive [3][5] are reworkings of the very same trial's data, not new studies. The only independent study of a broad, real-world patient population [2] found no difference between treated and untreated patients. So the panel saw a real but narrow positive result that has not been independently reproduced and is directly contradicted outside the enrolled subset.
One placebo-controlled RCT [1] in an enriched early-stage population showed a smaller decline in ALSFRS-R with edaravone, a least-squares mean difference of 2·49 (95% CI 0·99-3·98; p=0·0013). Post-hoc analyses of that same Study 19 cohort are consistent, finding reduced ALSFRS-R loss across respiratory subgroups [3] and lower King's-stage progression for edaravone than placebo (42.0% vs 55.9%) [5]. Against this, the one independent broad-population cohort [2] found no difference in progression (-0.91 vs -0.85 ALSFRS-R points/month; P=.37) and no benefit on survival or time to ventilation. The trial that supplies the positive signal [1] itself states there is no indication of effect in a wider population. The contested point: The division is whether the Study 19 effect [1] extends beyond its enriched enrolment or is confined to it. The only independent test in a broad population [2] found no benefit (P=.37), and the pivotal trial itself disclaims a wider effect, so the positive signal rests on one trial and its own re-analyses [3][5] rather than on replication.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Motor Neurone Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The sole positive RCT [1] showed benefit only in a heavily enriched early-stage subset and explicitly states there is 'no indication that edaravone might be effective in a wider population', yet the claim is unqualified about motor neurone disease generally.
Evidential independence is poor: three of four included sources ([1], [3], [5]) are re-analyses of the single Study 19 cohort, so the positive signal is one trial restated, not replicated.
Where it remains uncertain. The trial applies only to an enriched subset and disclaims wider effect [1], and the sole independent broad cohort found no progression difference (-0.91 vs -0.85 points/month; P=.37) [2].
Aleatory
The positive RCT rests on 134 analysed patients [1], so chance variation around a 24-week effect cannot be excluded from a single study of this size.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT demonstrating significantly slower ALSFRS-R decline with edaravone in the enriched population.
“There is no indication that edaravone might be effective in a wider population of patients with ALS who do not meet the criteria.”
Panel auditInternal validity: medium · scope of inference: Early-stage ALS patients meeting the enriched post-hoc inclusion criteria (grade 1-2, FVC ≥80%, definite/probable ALS, disease duration ≤2 years) over 24 weeks.Key limitations: highly selected subpopulation · small sample · LOCF imputation · 24-week duration only · authors warn against wider generalisation
Independent real-world cohort finding no slowing of functional decline — the key counter-evidence.
“Disease progression among 116 patients treated for a median of 13.9 months (IQR, 8.9-13.9 months) with edaravone did not differ from 116 patients treated for a median of 11.2 months (IQR, 6.4-20.0 months) with standard therapy (ALSFRS-R points/month, -0.91 [95% CI, -0.69 to -1.07] vs -0.85 [95% CI, -0.66 to -0.99]; P = .37).”
Panel auditInternal validity: medium · scope of inference: Real-world German ALS referral-centre patients with probable/definite ALS, including both trial-eligible (EFAS) and ineligible subgroups, over a median ~11-14 months.Key limitations: observational design · residual confounding possible · real-world unmasked outcomes · finite follow-up
Supportive post-hoc extension of Study 19, but not independent and authors call for a validating RCT.
“For the FVC24 ≥80%p subgroup, the changes in ALSFRS-R scores from baseline to week 48 were -7.63 for edaravone-edaravone vs -9.69 for placebo-edaravone, a difference of 2.05 (P = .034; 95% CI: 0.16, 3.94).”
Panel auditInternal validity: low · scope of inference: Study 19 participants stratified by FVC at 24 weeks, assessed through week 48 including the open-label phase.Key limitations: post-hoc subgroups · not pre-specified · open-label reference arm · authors call findings unvalidated
3 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One positive RCT in an enriched subpopulation with non-independent post-hoc support, offset by a null independent real-world cohort, places the unqualified claim in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory RCT in a broad population. The positive signal comes from one enriched trial [1] and its re-analyses [3][5], while the only independent broad comparison [2] is null; nothing in the corpus independently confirms the effect. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A new randomised, double-blind, placebo-controlled trial in an unenriched ALS population measuring ALSFRS-R decline.
Open question: Does edaravone slow ALSFRS-R decline in an unenriched, broad motor neurone disease population? Why it is still open: The one positive trial [1] is confined to an enriched subset and disclaims wider effect, and the only independent broad cohort [2] found no difference (P=.37).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19